Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma – A systematic reviewCapsule Summary
The rising incidence and consequent health care burden of nonmelanoma skin cancers, including cutaneous lymphomas, are a growing cause for concern. Oncolytic viruses (OVs) are emerging immunotherapies with limited literature on their use. We conducted a systematic review to evaluate their role in no...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | JAAD International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266632872500015X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849726989856931840 |
|---|---|
| author | Felicia Li Ling Ong, MBBS, MRCP Darryl Kai Xian Chin Yiming Zhu Choon Chiat Oh, MBBS, MRCP, MSc |
| author_facet | Felicia Li Ling Ong, MBBS, MRCP Darryl Kai Xian Chin Yiming Zhu Choon Chiat Oh, MBBS, MRCP, MSc |
| author_sort | Felicia Li Ling Ong, MBBS, MRCP |
| collection | DOAJ |
| description | The rising incidence and consequent health care burden of nonmelanoma skin cancers, including cutaneous lymphomas, are a growing cause for concern. Oncolytic viruses (OVs) are emerging immunotherapies with limited literature on their use. We conducted a systematic review to evaluate their role in nonmelanoma skin cancer and cutaneous lymphoma treatment (CRD42024526854). We identified 11 published studies involving a total of 20 patients (squamous cell carcinoma n = 3, Merkel cell carcinoma n = 7, cutaneous T cell lymphoma n = 9, basal cell carcinoma n = 1). OVs used include Talimogene laherparepvec (73%, n = 8), measles virus (9%, n = 1), vesicular stomatitis virus (9%, n = 1), and adenovirus (9%, n = 1). Complete response occurred in 67% (n = 2) of squamous cell carcinoma cases, 85% (n = 6) of Merkel cell carcinoma cases, and 11% (n = 1) of cutaneous T cell lymphoma cases. The most common adverse event was fever or flu-like symptoms (n = 5, 25%). Fourteen unpublished clinical trials investigating regimes such as OV monotherapy (43%, n = 6), combination therapy with existing immunotherapy (21%, n = 3), and comparing OV combination versus monotherapy (29%, n = 4) or versus immune checkpoint inhibitor alone (7%, n = 1). Overall, heterogeneity of existing studies significantly limits generalizability of results. Further research is needed to reveal the potential role of OVs in the future of nonmelanoma skin cancer and cutaneous lymphoma treatment. |
| format | Article |
| id | doaj-art-60eccabad3bd44b68c4cc2857dcee711 |
| institution | DOAJ |
| issn | 2666-3287 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JAAD International |
| spelling | doaj-art-60eccabad3bd44b68c4cc2857dcee7112025-08-20T03:10:00ZengElsevierJAAD International2666-32872025-06-012042010.1016/j.jdin.2024.11.010Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma – A systematic reviewCapsule SummaryFelicia Li Ling Ong, MBBS, MRCP0Darryl Kai Xian Chin1Yiming Zhu2Choon Chiat Oh, MBBS, MRCP, MSc3Department of Dermatology, Singapore General Hospital, Singapore, SingaporeYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeDepartment of Dermatology, Singapore General Hospital, Singapore, Singapore; Duke-NUS Medical School, Singapore, Singapore; Correspondence to: Choon Chiat Oh, MBBS, MRCP, MSc, Department of Dermatology, Singapore General Hospital, 20 College Rd, Academia, Singapore, 169856, Singapore.The rising incidence and consequent health care burden of nonmelanoma skin cancers, including cutaneous lymphomas, are a growing cause for concern. Oncolytic viruses (OVs) are emerging immunotherapies with limited literature on their use. We conducted a systematic review to evaluate their role in nonmelanoma skin cancer and cutaneous lymphoma treatment (CRD42024526854). We identified 11 published studies involving a total of 20 patients (squamous cell carcinoma n = 3, Merkel cell carcinoma n = 7, cutaneous T cell lymphoma n = 9, basal cell carcinoma n = 1). OVs used include Talimogene laherparepvec (73%, n = 8), measles virus (9%, n = 1), vesicular stomatitis virus (9%, n = 1), and adenovirus (9%, n = 1). Complete response occurred in 67% (n = 2) of squamous cell carcinoma cases, 85% (n = 6) of Merkel cell carcinoma cases, and 11% (n = 1) of cutaneous T cell lymphoma cases. The most common adverse event was fever or flu-like symptoms (n = 5, 25%). Fourteen unpublished clinical trials investigating regimes such as OV monotherapy (43%, n = 6), combination therapy with existing immunotherapy (21%, n = 3), and comparing OV combination versus monotherapy (29%, n = 4) or versus immune checkpoint inhibitor alone (7%, n = 1). Overall, heterogeneity of existing studies significantly limits generalizability of results. Further research is needed to reveal the potential role of OVs in the future of nonmelanoma skin cancer and cutaneous lymphoma treatment.http://www.sciencedirect.com/science/article/pii/S266632872500015Xepidemiologynonmelanoma skin canceroncolytic virusvirotherapy |
| spellingShingle | Felicia Li Ling Ong, MBBS, MRCP Darryl Kai Xian Chin Yiming Zhu Choon Chiat Oh, MBBS, MRCP, MSc Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma – A systematic reviewCapsule Summary JAAD International epidemiology nonmelanoma skin cancer oncolytic virus virotherapy |
| title | Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma – A systematic reviewCapsule Summary |
| title_full | Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma – A systematic reviewCapsule Summary |
| title_fullStr | Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma – A systematic reviewCapsule Summary |
| title_full_unstemmed | Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma – A systematic reviewCapsule Summary |
| title_short | Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma – A systematic reviewCapsule Summary |
| title_sort | oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma a systematic reviewcapsule summary |
| topic | epidemiology nonmelanoma skin cancer oncolytic virus virotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S266632872500015X |
| work_keys_str_mv | AT felicialilingongmbbsmrcp oncolyticviraltherapyfornonmelanomaskincancerandcutaneouslymphomaasystematicreviewcapsulesummary AT darrylkaixianchin oncolyticviraltherapyfornonmelanomaskincancerandcutaneouslymphomaasystematicreviewcapsulesummary AT yimingzhu oncolyticviraltherapyfornonmelanomaskincancerandcutaneouslymphomaasystematicreviewcapsulesummary AT choonchiatohmbbsmrcpmsc oncolyticviraltherapyfornonmelanomaskincancerandcutaneouslymphomaasystematicreviewcapsulesummary |